---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-017870"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2026-02-20T23:59:59+00:00"
generated_at: "2026-05-16T01:31:10.498314+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Organon Audit Committee completes biosimilar purchase review, finds no improper conduct

## Summary
- Audit Committee completed independent review of timing of biosimilar purchases from a supplier in prior years.
- Review found no evidence of improper conduct and no adjustments to previously issued financial statements.
- Company intends to file its Form 10-K for the year ended December 31, 2025 on time.
- No changes required to SEC disclosures related to the transactions reviewed.

## SEC filing metadata
- accession: 0001104659-26-017870
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2026-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465926017870/0001104659-26-017870-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465926017870/tm266880d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-017870
- JSON: https://secwatch.observer/filing/0001104659-26-017870.json
- Plain text: https://secwatch.observer/filing/0001104659-26-017870.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.